About Spring Bank

We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, SB 11285, is an intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist being developed for the treatment of certain cancers. We are developing a STING pathway portfolio of candidates with SB 11285, our STING antagonist compounds for the treatment of a broad range of inflammatory diseases and our STING agonist ADC program for potential oncology applications.

Our Mission

We are devoted to pioneering our proprietary Small Molecule Nucleic Acid Hybrid (SMNH) chemistry platform to discover and develop novel therapies to improve the lives of patients worldwide. We design our SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community.

Brief History

Since inception in 2002, we have sought to apply our small molecule nucleic acid hybrid (SMNH) chemistry platform toward the discovery and development of novel drugs.

SMNH- chemistry- platform